CAPR Stock Risk & Deep Value Analysis
Capricor Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CAPR Stock
We analyzed Capricor Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CAPR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CAPR Risk Analysis & Red Flags
What Could Go Wrong
The most significant risk is the FDA issuing a Complete Response Letter for Deramiocel on or around August 22, 2026. This would trigger a massive re-evaluation of the company's valuation, likely wiping out 50-70% of its current $1.65B market cap and forcing additional capital raises to fund further clinical work, thereby significantly diluting existing shareholders.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Company is currently pre-revenue with increasing quarterly net losses ($33.9M in Q1 2026).
- ⚠
Sole pipeline focus on one drug (Deramiocel) for near-term commercialization, creating high single-asset risk until approval.
- ⚠
Unspecified legal action with NS Pharma could complicate Deramiocel's commercialization and patient access post-approval.
- ⚠
Heavy reliance on a single regulatory decision (FDA PDUFA on Aug 22, 2026) for future viability and stock re-rating.
Upcoming Risk Events
- 📅
FDA issues a Complete Response Letter (CRL) for Deramiocel BLA (August 22, 2026): This would likely trigger a significant stock price decline, requiring additional clinical trials and dilutive financing.
- 📅
Adverse outcome in NS Pharma legal action (H2 2026 - H1 2027): Could restrict commercial distribution or impose substantial financial penalties, impacting early sales and market penetration of Deramiocel.
When to Reconsider
- 🚪
FDA issues a Complete Response Letter (CRL) for Deramiocel BLA on August 22, 2026.
- 🚪
Q1 2027 revenue run-rate for Deramiocel falls below $30M, indicating very poor market adoption.
- 🚪
Cash, cash equivalents, and marketable securities fall below $100M without a clear path to profitability or new financing by Q3 2027.
Unlock CAPR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Capricor Therapeutics Inc (CAPR) Do?
Market Cap
$1.67B
Sector
Healthcare
Industry
Biotechnology
Employees
160
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Visit Capricor Therapeutics Inc WebsiteInvestment Thesis
If the FDA approves Deramiocel (CAP-1002) by the August 22, 2026 PDUFA date, it will unlock access to the multi-billion dollar Duchenne Muscular Dystrophy (DMD) market, where Deramiocel's unique cell therapy mechanism offers significant clinical advantages and potential regulatory exclusivity. This approval would de-risk the investment significantly, allowing the company to rapidly scale commercialization and achieve $1.5B+ in annual peak sales potential, leading to a substantial valuation re-rating from its current $1.65B market cap. This is bullish because the market currently prices in high regulatory uncertainty.
Is CAPR Stock Undervalued?
Unlock the full AI analysis for CAPR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CAPR Price Targets & Strategy
12-Month Target
$77.85
Bull Case
$173.00
Bear Case
$8.50
Valuation Basis
3x projected peak sales of $1.5B post-approval / 57.8M implied shares outstanding = $77.85/share
Entry Strategy
Given the binary nature of the upcoming PDUFA, aggressive investors might dollar-cost average between $25-$30 prior to August 2026. More conservative investors should await FDA decision confirmation and evaluate post-approval price action, looking for consolidation above $40.
Exit Strategy
Take initial 30-50% profit at $70-$80 post-approval re-rating. Consider further profit-taking at $150-$170 for longer-term growth. Implement a stop-loss at $20 prior to PDUFA, or $40 post-approval if initial commercialization falters.
Portfolio Allocation
7-15% for aggressive risk tolerance; 3-7% for moderate risk tolerance post-approval.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is CAPR Financially Healthy?
Valuation
P/E Ratio
-13.44
Forward P/E
252.19
EV/EBITDA
-14.71
PEG Ratio
1.01
Price/Book
6.04
Profitability
Operating Margin
-191.13%
Net Margin
-181.71%
Return on Equity
-59.27%
EPS
$-2.31
Balance Sheet
Current Ratio
9.01
Quick Ratio
8.88
Debt/Equity
0.02
Cash Flow
EBITDA
-$118.00M
Other
Beta (Volatility)
0.30
Does CAPR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
Moderate. Deramiocel's unique mechanism and potential orphan drug status could provide a durable competitive advantage for 10-15 years, especially if it addresses specific unmet needs or patient populations not fully covered by existing or emerging therapies.
Moat Erosion Risks
- •Emergence of superior gene therapies or small molecules for DMD that offer broader efficacy or better safety profiles.
- •Patent expiry or challenges to its intellectual property portfolio.
- •Manufacturing complexity and cost associated with cell therapy compared to other drug modalities.
CAPR Competitive Moat Analysis
Sign up to see competitive advantages
CAPR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Cautiously Bullish, with significant speculation around the upcoming PDUFA decision.
Institutional Sentiment
Not verifiable from provided sources. Assumed Neutral.
Insider Activity (Form 4)
Not verifiable from provided sources. Assumed Normal activity.
Options Flow
Normal options activity, with potential for increased speculative volume closer to the August PDUFA date.
Earnings Intelligence
Next Earnings
Estimated late August 2026 (for Q2 2026 results)
Surprise Probability
High (as a pre-revenue company, focus is on cash burn and PDUFA updates, not revenue/EPS beats)
Historical Earnings Pattern
Likely volatile share price reactions to earnings reports, driven more by regulatory updates and cash runway than by traditional financial metrics.
Key Metrics to Watch
Competitive Position
Top Competitor
Sarepta Therapeutics (SRPT)
Market Share Trend
Currently 0%. If approved, aims to gain significant market share in the DMD therapeutic landscape.
Valuation vs Peers
CAPR is pre-revenue and pre-commercial, so it trades at a significant discount to revenue-generating DMD competitors like Sarepta Therapeutics (SRPT, $13B+ market cap) but commands a valuation based on its late-stage pipeline potential.
Competitive Advantages
- •Unique cell therapy mechanism (cardiosphere-derived cells) with broad applicability across DMD mutations.
- •Potential for first-in-class approval and regulatory exclusivity in certain DMD patient populations.
- •Focus on cardiac and skeletal muscle function, potentially offering benefits complementary to gene therapies.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive CAPR Stock Higher?
Near-Term (0-6 months)
- •FDA PDUFA target action date for Deramiocel (August 22, 2026): Approval would trigger significant de-risking and unlock commercialization, potentially leading to $1.5B+ in annual peak sales.
- •Q2 2026 Earnings Report (estimated late August 2026): Focus on cash burn rate (target under $35M), updates on commercialization readiness post-PDUFA, and commentary on NS Pharma legal action.
Medium-Term (6-18 months)
- •Deramiocel commercial launch & initial sales data (Q4 2026 - Q2 2027): First revenue generation from product sales. Hitting an annualized run-rate of $50M+ by Q2 2027 would signal strong market adoption.
- •Resolution or clear path forward for NS Pharma legal action (H2 2026 - H1 2027): Clarity on commercialization strategy and market access, enabling full commercial reach to all US DMD patients.
Long-Term (18+ months)
- •Expansion of Deramiocel indications/geographies (2028+): Beyond initial DMD approval, pursuit of additional muscular dystrophies or international markets (e.g., EU) could double the addressable patient population.
- •Sustained achievement of $1.5B+ annual peak sales for Deramiocel (2030+): Establishing market leadership in DMD with potential for long-term revenue growth and margin expansion.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for CAPR?
- ✓
FDA decision on Deramiocel BLA (August 22, 2026).
- ✓
Quarterly Deramiocel net sales (Q4 2026 onwards) – crossing $15M/quarter by Q2 2027.
- ✓
Resolution and specific terms of the NS Pharma legal action.
- ✓
Quarterly cash burn rate – any significant increase above $35M/quarter for two consecutive quarters.
Bull Case Analysis
Sign up free to see the bull case
Competing with CAPR
See how Capricor Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Capricor Therapeutics Inc CAPR | $1.7B | 7.8 | -13.4 | — | -181.7% | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Capricor Therapeutics Inc Makes Money
Capricor Therapeutics is a clinical-stage biotechnology company focused on developing novel cell and exosome-based therapeutics. Currently pre-revenue, its business model centers on developing and gaining regulatory approval for its lead product candidate, Deramiocel (CAP-1002), for the treatment of Duchenne Muscular Dystrophy (DMD). If approved, the company will generate revenue through the sale of Deramiocel, likely leveraging partnerships for distribution, to address a critical unmet medical need in the DMD patient population.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Capricor Therapeutics Inc (CAPR)?
As of June 2, 2026, Capricor Therapeutics Inc has a DVR Score of 7.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Capricor Therapeutics Inc?
Capricor Therapeutics Inc's market capitalization is approximately $1.7B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Capricor Therapeutics Inc use?
CAPR is the ticker symbol for Capricor Therapeutics Inc. The company trades on the NCM.
What is the risk level for CAPR stock?
Our analysis rates Capricor Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CAPR?
Capricor Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -13.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is CAPR stock profitable?
Capricor Therapeutics Inc has a profit margin of -181.7%. The company is currently unprofitable.
How often is the CAPR DVR analysis updated?
Our AI-powered analysis of Capricor Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 2, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CAPR (Capricor Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.